Hikma Pharmaceuticals PLC
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Hikma Pharmaceuticals PLC (HKMPF) develops, manufactures and markets a broad portfolio of generic, branded generic, in-licensed patented and specialty pharmaceutical products across injectables, oral solids, inhalables and nasal sprays; core offerings span sterile injectables for oncology, cephalosporins, pain management and respiratory therapies, alongside oral generics in cardiovascular, diabetes, central nervous system, dermatology and other categories, specialty products including biosimilars such as STARJEMZA (ustekinumab-hmny) and compounded medicines; the company provides contract manufacturing services and in-licensed brands to hospitals, clinics and pharmacies worldwide. Headquartered in London, UK, and founded in 1978 in Amman, Jordan, Hikma operates manufacturing facilities in the US, six MENA countries, Portugal, Italy, Germany and other locations, serving primary markets in North America, the Middle East and North Africa (MENA) and Europe. Recent developments include the 2024 acquisition of Xellia Pharmaceuticals' US finished dosage form business to bolster injectables capacity and pipeline; agreement to acquire 17 Takeda brands for enhanced branded profitability; launch of its first GLP-1 product liraglutide and 89 new products including 12 in the US; expansion of generics contract manufacturing via a major global partnership slated for 2027 contributions; January 2025 exclusive commercial partnership with Emergent BioSolutions for Kloxxado naloxone nasal spray; November 2025 exclusive MENA agreement with DGI Group for Claritag and strengthened partnership with Celltrion for biosimilars; alongside a $250 million six-year financing deal with IFC in July 2025 to support MENA production and access.
Company News
Panmure Liberum raises Hikma target price to 1,900p
Jefferies lifts Hikma target as CMO deal underpins growth story
Citi sees Hikma discount as unwarranted after upgrade to forecasts
Hikma boost as broker raises price target
Hikma jumps 10% as brokers point to profit beat and undemanding rating
Hikma jumps 10% as brokers point to profit beat and undemanding rating
Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi
Hikma recovery story still has further to run after recent rally, says Panmure
Citi starts Hikma at 'buy' with strategy reset offering compelling entry point
London BTC's Black Star project hits 16g/t gold as Nevada portfolio grows to four
AtaiBeckley to be acquired by Lilly in deal valued at up to $3.8 billion
Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval
Hikma Pharmaceuticals PLC (HKMPY) Sales/ Trading Statement Call Transcript
UK's Hikma Pharmaceuticals reiterates 2026 outlook despite higher costs from Iran war
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Prepared Remarks Transcript
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Transcript
Hikma Pharma tumbles on softer guidance as buyback fails to soften pill
Financial Review: Century Therapeutics (NASDAQ:IPSC) and Hikma Pharmaceuticals (OTCMKTS:HKMPF)
Head to Head Contrast: Hikma Pharmaceuticals (OTCMKTS:HKMPF) vs. ProPhase Labs (NASDAQ:PRPH)
Hikma falls to three-year low as CEO steps down with immediate effect